

### Guidelines should be international and based on solid evidence and not take into account local resources or availabilities

Jan Tordoir, Maastricht



CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE CONTROVERSIES & UPDATES IN VASCULAR SURGERY JANUARY 19-21 2017 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER JANUARY 19-21 2017 PARIS, FRANCE

www.cacvs.org

### **Faculty Disclosure**

Jan H.M. Tordoir

I have no financial relationships to disclose.

### Fifty years of vascular access in HD patients

- Renal failure and renal replacement therapy have become an epidemic disease
- HD population demographics changed from young, non-comorbid to elderly, multiple comorbid patients
- Great burden on dialysis facilities and healthcare providers and costs
- Improvement in dialysis modalities/VA techniques and AVG material
- Multiple guidelines notify on preferred access: 1. AVF ; 2. AVG; 3. CVC



Vascular Access Clinical Practice Guidelines of the European Society of Vascular Surgery






<<



www.european-renal-best-practice.org






arteriovenous

AVF — The first choice for hemodialysis


### **Evidence-based guidelines**



### **Evidence & recommendations**

Grade of		lla	llb	
recommendation	Strong	Moderate	Weak	Recommendation
recommendation	recommendation	recommendation	recommendation	not to do
	to do	to do	to do	
<b>Conclusions of</b>	Benefits >>> risk &	Benefits >> risk &	Benefits >= risks &	No benefit /
evidence	burdens	burdens	burdens	Potentially harm
A High level of				
evidence			and the second	
Consistent	Strong	Moderate	Weak	Recommendation
evidence from well	recommendation	recommendation	recommendation	based on high level
performed and	based on high level	based on high level	based on high level	of evidence
high quality studies	of evidence	of evidence	of evidence	
or systematic				
reviews (low risk of				
bias, direct,				
consistent, precise)				
B Moderate /Low				
level of evidence				
Evidence from	Strong	Moderate	Weak	Recommendation
studies or	recommendation	recommendation	recommendation	based on
systematic reviews	based on	based on	based on	moderate/ low
with few important	moderate/ low	moderate/ low	moderate/ low	level of evidence
limitations	level of evidence	level of evidence	level of evidence	
C Very low level of				
evidence				
Evidence from	Strong	Moderate	Weak	Recommendation
studies with	recommendation	recommendation	recommendation	based on very low
serious flaws.	based on expert	based on very low	based on very low	level of evidence
Only expert	opinion	level of evidence	level of evidence	Expert opinion
opinion, or		Diverging expert	Diverging expert	
standards of care		opinions	opinions	
	14/		in recommendations:	
	We recommend	We suggest	We might suggest	We do not
	We should	Is reasonable	Might be	recommend
	Is recommended	Is probably	reasonable	Should not be
	Is indicated	recommended	Might be	performed
	ls useful	Can be useful	considered	ls not useful
	Is beneficial	Can be beneficial	Usefulness is	Is not beneficial
	Is effective	Can be effective	unknown	Is not effective
				Is potentially
				harmful

### Vascular Access Practice Reality of evidence-based guidelines



32

46

5

ESVS vascular access guidelines (release march 2017)

### **PUB MED "Hemodialysis Vascular Access"**

# 2007-201626 meta analyses94 systematic reviews86 randomized studies

**GRADE Working Group grades of evidence** 

- High quality: Further research is very unlikely to change our confidence in the estimate of effect
- Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
- Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
- Very low quality: We are very uncertain about the estimate

Analysis I.I. Comparison I Preoperative vessel imaging by ultrasound mapping versus standard preoperative care, Outcome I Fistulae created.

Review: Preoperative vascular access evaluation for haemodialysis patients

Comparison: I Preoperative vessel imaging by ultrasound mapping versus standard preoperative care

Outcome: | Fistulae created

Study or subgroup	Ultrasound mapping n/N	Control n/N		Risk Ratio M- ndom,95% Cl	Weight	Risk Ratio M- H,Random,95%
Smith 2014	30/38	25/39	-		10.7 %	1.23 [ 0.92, 1.64 ]
Shiftin 2011						1.25 [ 0.72, 1.01 ]
Zhang 2006	29/33	24/35			12.5 %	1.28 [ 0.99, 1.66 ]
Ferring 2010	107/112	101/106		-	38.1 %	1.00 [ 0.95, 1.06 ]
Nursal 2006	35/35	35/35		-	38.6 %	1.00 [ 0.95, 1.06 ]
Total (95% CI)	218	215		•	1 <b>00.0</b> %	1.06 [ 0.95, 1.18 ]
	ound mapping), 185 (Control)					
Heterogeneity: $Tau^2 = 0$ .	01; $Chi^2 = 12.66$ , $df = 3$ (P =	0.01); l <sup>2</sup> =76%				
Test for overall effect: Z	= 0.98 (P = 0.32)					
Test for subgroup differer	nces: Not applicable					
			0.5 0.7	I I.5	2	
			More with control	More with	ultrasound	

Analysis I.2. Comparison I Preoperative vessel imaging by ultrasound mapping versus standard preoperative care, Outcome 2 Matured fistulae.

Review: Preoperative vascular access evaluation for haemodialysis patients

Comparison: I Preoperative vessel imaging by ultrasound mapping versus standard preoperative care

Outcome: 2 Matured fistulae

Study or subgroup	Ultrasound mapping	Control		Risk Ratio M- ndom,95%	Weight	Risk Ratio M- H,Random,95%
	n/N	n/N		ĊI		Ċ
Zhang 2006	29/33	28/35	-	•	32.6 %	1.10 [ 0.89, 1.35 ]
Nursal 2006	23/35	23/35		<b>-</b>	12.4 %	1.00 [ 0.71, 1.40 ]
Ferring 2010	88/112	73/106			55.1 %	1.14 [ 0.97, 1.34 ]
Total (95% CI)	180	176		•	100.0 %	1.11 [ 0.98, 1.25 ]
Total events: 140 (Ultraso	ound mapping), 124 (Control)					
Heterogeneity: $Tau^2 = 0$ .	0; Chi <sup>2</sup> = 0.49, df = 2 (P = 0.78	3); I <sup>2</sup> =0.0%				
Test for overall effect: Z =	= 1.70 (P = 0.089)					
Test for subgroup differer	nces: Not applicable					
			0.5 0.7	I I.5	2	
			More with control	More with	ultrasound	


The Cochrane Library 2015, Issue 9

Analysis I.3. Comparison I Preoperative vessel imaging by ultrasound mapping versus standard preoperative care, Outcome 3 Fistulae used for dialysis.

Review: Preoperative vascular access evaluation for haemodialysis patients


Comparison: I Preoperative vessel imaging by ultrasound mapping versus standard preoperative care

Outcome: 3 Fistulae used for dialysis



The Cochrane Library 2015, Issue 9

#### **Risk of bias in randomized studies**



The Cochrane Library 2015, Issue 9

Preoperative vessel imaging by duplex ultrasound mapping versus standard preoperative care for arteriovenous access creation in haemodialysis (HD) patients

Patient or population: HD patients with arteriovenous fistulas Intervention: routine preoperative vessel imaging by ultrasound versus standard preoperative care

Outcomes	Illustrative comparative	risks* (95% CI)	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Standard care	Vessel imaging by ultra- sound				
Fistulas created	Study population		RR 1.02	433 (4)	0000	
Assessed by surgeon <sup>1</sup> Follow-up: 1 day	909 per 1000	<b>927 per 1000</b> (855 to 1000)	(0.94 to 1.12)		very low <sup>2</sup> , <sup>3</sup>	
	Moderate risk					
	953 per 1000	<b>972 per 1000</b> (896 to 1000)				
Fistulas matured Clinical assessment by experienced HD nurse Follow-up: 6 to 12 months	705 per 1000	<b>782 per 1000</b> (690 to 881)	<b>RR 1.11</b> (0.98 to 1.25)	356 (3)	⊕⊕⊖⊖ Iow <sup>3,;</sup>	
Fistulas used for dialysis Clinical assessment by HD nurse Follow-up: 6 to 24 months	716 per 1000	<b>802 per 1000</b> (709 to 917)	<b>RR 1.12</b> (0.99 to 1.28)	286 (2)	⊕⊕⊖⊖ low <sup>3</sup> .•	

 Based on four small studies, preoperative vessel imaging did not improve fistula outcomes compared with standard care. Adequately powered prospective studies are required to fully answer this question

### Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (Review)

#### Analysis 7.1. Comparison 7 Clopidogrel versus placebo, Outcome 1 Graft thrombosis.

Review: Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts


Comparison: 7 Clopidogrel versus placebo

Outcome: I Graft thrombosis

Study or subgroup	Clopidogrel	Placebo	Odds Ratio M-	Weight	Odds Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Ghorbani 2009 (1)	2/46	10/47		29.5 %	0.17 [ 0.03, 0.82 ]
Dember 2008 (2)	53/436	84/430		70.5 %	0.57 [ 0.39, 0.83 ]
Total (95% CI)	482	477	•	100.0 %	0.40 [ 0.13, 1.19 ]
Total events: 55 (Clopidog	rel), 94 (Placebo)				
Heterogeneity: $Tau^2 = 0.4$	I; $Chi^2 = 2.18$ , $df = 1$ (P	= 0.   4);   <sup>2</sup> =54%			
Test for overall effect: $Z =$	I.65 (P = 0.098)				
Test for subgroup difference	es: Not applicable				
			<u> </u>		
			0.001 0.01 0.1 1 10 100 1000		
			Favours clopidogrel Favours placebo		

Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD002786

## Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (Review)



Low risk of bias

Unclear risk of bias

High risk of bias

Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD002786

Multicenter randomized study Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis

Randomized study

•Multicenter study (9 US centers) inclusion 866

- <sup>pat</sup> <u>8 fistulae per center/per year!!!</u>
- •Pr

<u> 6 fistulae per surgeon/ per year!!!</u>

•Fistula surgeries were performed at 27 hospitals by

71 surgeons

### **Enough local resources or availabilities?**

 Adherence to study medication was present in 87% of participants assigned to clopidogrel and for 86% of participants assigned to placebo

#### Multicenter randomized study Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis

Table 2. Fistula Thrombosis


	No. (%) of	Patients	
	Clopidogrel (n = 435) <sup>a</sup>	Placebo (n = 431) <sup>a</sup>	Relative Risk (95% Confidence Interval) <sup>b</sup>
Thrombosis at 6 wk (all patients)	53 (12.2)	84 (19.5)	0.63 (0.46-0.97) <sup>c</sup>
By location Forearm fistula	31 (12.9)	60 (24.7)	0.53 (0.36-0.77)
Upper arm fistula	22 (11.3)	24 (12.8)	0.89 (0.52-1.53)

### Primary failure rate 61.8 and 59.5%!!!

	No. (%) of	Patients	
	Clopidogrel (n = 385) <sup>a</sup>	Placebo (n = 373) <sup>a</sup>	Relative Risk (95% Confidence Interval) <sup>b</sup>
Suitability failure (all patients)	238 (61.8)	222 (59.5)	1.05 (0.94-1.17) <sup>c</sup>
By location Forearm fistula	144 (66.9)	137 (64.0)	1.05 (0.92-1.20)
Upper arm fistula	94 (55.3)	85 (53.4)	1.05 (0.87-1.27)
By failure reason Fistula abandoned with no expectation of future use	115 (29.9)	134 (35.9)	0.85 (0.69-1.03)
Fistula not yet in use despite treatment with dialysis	57 (14.8)	47 (12.6)	1.17 (0.83-1.66)
Fistula in use during ascertainment period but failed to meet suitability criteria	66 (17.1)	41 (11.0)	1.56 (1.08-2.24)


JAMA 2008;299(18):2164-2171

#### The Effect of Anastomosis and Graft Geometry on AVG Patency in Hemodialysis Patients a systematic review



	Modified ePTFE	AVGs	Standard ePTFE	AVGs		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Dammers et al. 2003	7	52	5	57	16.0%	1.53 [0.52, 4.54]	
Ko et al. 2009	1	47	6	42	5.6%	0.15 [0.02, 1.19]	←
Lemson et al 2002	4	20	2	20	8.9%	2.00 [0.41, 9.71]	
Lemson et al. 2000	11	59	10	61	24.3%	1.14 [0.52, 2.48]	
Polo et al. 2004	4	35	5	35	13.3%	0.80 [0.23, 2.73]	
Sorom et al. 2002	9	24	16	24	31.8%	0.56 [0.31, 1.01]	
Total (95% CI)		237		239	100.0%	0.85 [0.51, 1.43]	Secondary patency
Total events	36		44				
Heterogeneity: Tau² = ( Test for overall effect: Z			= 0.19); I <sup>2</sup> = 32%				0.1 0.2 0.5 1 2 5 10 Favours Modified AVG Favours Standard AVG

### The Effect of Anastomosis and Graft Geometry on AVG Patency in Hemodialysis Patients a systematic review



Lowr	isk of bias			ear risk of	hiae		Hi	gh risk of bi	99	
					09	6	25%	50%	75%	100
				Other bi	as					
	Se	lective rep	orting (re	porting bia	as)					
	Incompl	ete outcor	ne data (	attrition bia	as)					
Bli	nding of outcon	ne assess	ment (de	etection bia	as)					
Blinding of	participants an	d personn	el (perfor	mance bia	as)					
	Allocati	n concea	lment (se	election bia	as)					
	Random seque	nce gene	ration (se	election bia	as)					

#### **Risk of Bias analysis overview**



No blinding for surgeon or patient



Primary patency was only defined as "functioning well" making it is assessment subjective

### Meta-analysis Surgical vs mechanical thrombectomy vs pharmacomechanical thrombolysis for thrombosed dialysis grafts

45 / 59 6 / 15 6 / 10 70 / 82 127 / 166 =2.72 df=3 p=0.44	31/56 4/16 7/10 53/71 95/153		32.0 3.9 7.0 57.1	1.38(1.05,1.81) 1.60(0.56,4.58) 0.86(0.45,1.64) 1.14(0.97,1.35)
6 / 10 70 / 82 127 / 166	7/10 53/71 95/153		7.0 57.1	0.86[0.45,1.64] 1.14[0.97,1.35]
70/82	53/71 95/153		57.1	1.14[0.97,1.35]
127/166	95/153	•		
		•	00.0	
2.72 df=3 p=0.44				1.22[1.05,1.40]
0.007	+			
	Surgery n/N	F <mark>R</mark> (95%C Fixed)	V/eight %	RR (95%C! Fixed)
18/24	10/19		13.2	1.43[0.68,2.31]
34/39	30 / 41	- <b>8</b>	34.6	1.19[0.96,1.49]
54 / 59	43/56	<b>1</b>	52.2	1.19[1.01,1.40]
54759				
106/122	83/116	•	00.0	1.22[1.07,1.40]
	+ + - + - +	•	100.0	1.22[1.07,1.40]
	Thrombectomy imary Patency Endovascular n/N 18 / 24	Thrombectomy vs. Endovascula imary Patency Endovascular Surgery n/N n/N 18/24 10/19	Thrombectomy vs. Endovascular Thrombectomy imary Patency Endovascular Surgery FR n/N n/N (95%C Fixed) 18/24 10/19	Thrombectomy vs. Endovascular Thrombectomy imary Patency Endovascular Surgery FR V/eight n/N n/N (95%C Fixed) % 18/24 10/19 13.2

Comparison: 01 Surgical Thrombectomy vs. Endovascular Thrombectomy

J Vasc Surg. 2002;36(5):939-45

### Meta-analysis Surgical vs mechanical thrombectomy vs pharmacomechanical thrombolysis for thrombosed dialysis grafts

- Meta-analysis supports the use of surgical techniques for graft thrombectomy
- However several flaws of included randomized studies:
  - small numbers of included patients
  - different thrombectomy devices
  - additional thrombolysis in some studies
  - one multicenter study with large differences in technical success rate (25% to 100%)
  - different surgical procedures

### Evidence-based guidelines & quality of studies

#### What about:

•Quality of randomized studies

Power analysis

Randomization protocol

•Number of including centers/ included patients per center

Violation of study protocol

Missing values

Local practice & experience